Loading company…
Tsuruoka-based Metcela Inc. develops regenerative medicine therapies, led by JRM-001 for pediatric congenital heart disease.
Founded in 2016 and headquartered in Tsuruoka, Japan, Metcela Inc. develops cell-based regenerative therapies, with its lead product JRM-001 aimed at pediatric congenital heart disease. It generates revenue by commercializing JRM-001, selling directly to hospitals and working with healthcare institutions. In June 2022 the company raised JPY 1.27 billion in Series C funding co-led by CYBERDYNE, Inc. and CEJ Capital, with participation from Japan Lifeline, Reazon Holdings and returning investor Sony Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in